WO2001007612A3 - Receptors and associated proteins - Google Patents

Receptors and associated proteins Download PDF

Info

Publication number
WO2001007612A3
WO2001007612A3 PCT/US2000/020035 US0020035W WO0107612A3 WO 2001007612 A3 WO2001007612 A3 WO 2001007612A3 US 0020035 W US0020035 W US 0020035W WO 0107612 A3 WO0107612 A3 WO 0107612A3
Authority
WO
WIPO (PCT)
Prior art keywords
recap
associated proteins
receptors
provides
expression
Prior art date
Application number
PCT/US2000/020035
Other languages
French (fr)
Other versions
WO2001007612A2 (en
Inventor
Janice Au-Young
Olga Bandman
Y Tom Tang
Henry Yue
Yalda Azimzai
Neil Burford
Mariah R Baughn
Dyung Aina M Lu
Jennifer L Hillman
Chandra Patterson
Preeti Lal
Original Assignee
Incyte Genomics Inc
Au Young Janice
Olga Bandman
Y Tom Tang
Henry Yue
Yalda Azimzai
Neil Burford
Mariah R Baughn
Dyung Aina M Lu
Jennifer L Hillman
Chandra Patterson
Preeti Lal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Genomics Inc, Au Young Janice, Olga Bandman, Y Tom Tang, Henry Yue, Yalda Azimzai, Neil Burford, Mariah R Baughn, Dyung Aina M Lu, Jennifer L Hillman, Chandra Patterson, Preeti Lal filed Critical Incyte Genomics Inc
Priority to JP2001512881A priority Critical patent/JP2003505083A/en
Priority to AU62323/00A priority patent/AU6232300A/en
Priority to CA002379801A priority patent/CA2379801A1/en
Priority to EP00948891A priority patent/EP1200587A2/en
Publication of WO2001007612A2 publication Critical patent/WO2001007612A2/en
Publication of WO2001007612A3 publication Critical patent/WO2001007612A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

The invention provides human receptors and associated proteins (RECAP) and polynucleotides which identify and encode RECAP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with expression of RECAP.
PCT/US2000/020035 1999-07-21 2000-07-21 Receptors and associated proteins WO2001007612A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2001512881A JP2003505083A (en) 1999-07-21 2000-07-21 Receptors and related proteins
AU62323/00A AU6232300A (en) 1999-07-21 2000-07-21 Receptors and associated proteins
CA002379801A CA2379801A1 (en) 1999-07-21 2000-07-21 Receptors and associated proteins
EP00948891A EP1200587A2 (en) 1999-07-21 2000-07-21 Receptors and associated proteins

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US14523299P 1999-07-21 1999-07-21
US60/145,232 1999-07-21
US15857899P 1999-10-07 1999-10-07
US60/158,578 1999-10-07
US16519299P 1999-11-12 1999-11-12
US60/165,192 1999-11-12

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/935,190 Division US20050037466A1 (en) 1999-07-21 2004-09-08 Receptors and associated proteins

Publications (2)

Publication Number Publication Date
WO2001007612A2 WO2001007612A2 (en) 2001-02-01
WO2001007612A3 true WO2001007612A3 (en) 2001-06-07

Family

ID=27386232

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/020035 WO2001007612A2 (en) 1999-07-21 2000-07-21 Receptors and associated proteins

Country Status (5)

Country Link
EP (1) EP1200587A2 (en)
JP (1) JP2003505083A (en)
AU (1) AU6232300A (en)
CA (1) CA2379801A1 (en)
WO (1) WO2001007612A2 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020137890A1 (en) * 1997-03-31 2002-09-26 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6573095B1 (en) 1998-04-29 2003-06-03 Genesis Research & Development Corporation Limited Polynucleotides isolated from skin cells
CA2382018A1 (en) * 1999-08-16 2001-02-22 Human Genome Sciences, Inc. Retinoid receptor interacting polynucleotides, polypeptides, and antibodies
AU1575601A (en) * 1999-10-27 2001-05-08 Pharmacia & Upjohn Company G protein-coupled receptors expressed in brain
CA2389672A1 (en) * 1999-11-03 2001-05-10 Merck Patent Gesellschaft Mit Beschraenkter Haftung Human gpr27-like g-protein coupled receptor polypeptide and polynucleotide sequences
AU2001243283A1 (en) * 2000-02-25 2001-09-03 Millennium Pharmaceuticals, Inc. 44576, a novel g-protein coupled receptor and uses therefor
AU2001260847A1 (en) * 2000-05-24 2001-12-03 Genesis Research And Development Corporation Limited Compositions isolated from skin cells and methods for their use
AU2002304826A1 (en) * 2001-03-01 2002-10-08 Lion Bioscience Ag Cofactors of the liver x receptor alpha and methods of use
US20030068636A1 (en) * 2001-06-21 2003-04-10 Millennium Pharmaceuticals, Inc. Compositions, kits and methods for identification, assessment, prevention, and therapy of breast and ovarian cancer
US20030207288A1 (en) * 2001-08-20 2003-11-06 Lewin David A. GPCR-like retinoic acid-induced gene 1 protein and nucleic acid
WO2003023009A2 (en) * 2001-09-07 2003-03-20 Incyte Genomics, Inc. G-protein coupled receptors
WO2004001060A2 (en) * 2002-06-20 2003-12-31 Bristol-Myers Squibb Company Identification and regulation of a g-protein coupled receptor, rai-3
JP4583007B2 (en) * 2002-07-16 2010-11-17 住友化学株式会社 Novel G-protein and use thereof
US20080260744A1 (en) 2002-09-09 2008-10-23 Omeros Corporation G protein coupled receptors and uses thereof
EP3807636B1 (en) * 2018-06-15 2024-01-31 F. Hoffmann-La Roche AG A system for identification of antigens recognized by t cell receptors expressed on tumor infiltrating lymphocytes

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998045437A2 (en) * 1997-04-10 1998-10-15 Genetics Institute, Inc. SECRETED EXPRESSED SEQUENCE TAGS (sESTs)

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998045437A2 (en) * 1997-04-10 1998-10-15 Genetics Institute, Inc. SECRETED EXPRESSED SEQUENCE TAGS (sESTs)

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL 12 December 1999 (1999-12-12), PENG Y. ET AL.: "Homo sapiens retinoid X receptor interacting protein mRNA.", XP002153302 *
DATABASE EMBL 15 March 1995 (1995-03-15), SEOL W. ET AL.: "Mus musculus X receptor interacting protein (RIP110) mRNA.", XP002153300 *
DATABASE EMBL 31 December 1998 (1998-12-31), STRAUSBERG R.: "Retinoid X receptor interacting protein.", XP002153301 *
SEOL W. ET AL.: "Isolation of proteins that interact specifically with the retinoid X receptor: Two novel orphan receptors.", MOLECULAR ENDOCRINOLGY, vol. 9, no. 1, 1995, pages 72 - 85, XP000651076 *

Also Published As

Publication number Publication date
JP2003505083A (en) 2003-02-12
CA2379801A1 (en) 2001-02-01
EP1200587A2 (en) 2002-05-02
AU6232300A (en) 2001-02-13
WO2001007612A2 (en) 2001-02-01

Similar Documents

Publication Publication Date Title
WO2001012662A3 (en) Membrane associated proteins
WO1999061471A3 (en) Human transmembrane proteins
WO2000015793A3 (en) Human gpcr proteins
WO2000034477A3 (en) Neuron-associated proteins
WO2000021988A3 (en) Human ankyrin family protein
WO2000018922A3 (en) Human carbohydrate-associated proteins
WO2000029583A3 (en) Immunoglobulin superfamily proteins
WO1999058692A3 (en) Human apoptosis associated proteins
WO2000009709A3 (en) Proteases and associated proteins
WO2001007612A3 (en) Receptors and associated proteins
WO2000026245A3 (en) Human membrane transport proteins
WO2000017355A3 (en) Human cytoskeleton associated proteins
WO2001005970A3 (en) Gtp-binding protein associated factors
WO2001020004A3 (en) Protein phosphatase and kinase proteins
WO2000052151A3 (en) Human secretory proteins
WO2000078953A3 (en) Human transport proteins
WO2000014251A3 (en) Human transferase proteins
WO2000056891A3 (en) Human transmembrane proteins
WO2000028032A3 (en) Human cell surface receptor proteins
WO2000020590A3 (en) G-protein coupled receptor proteins
WO2001007471A3 (en) Cell cycle and proliferation proteins
WO1999061614A3 (en) Human socs proteins
WO2001044448A3 (en) Human oxidoreductase proteins
WO2000031263A3 (en) Gtpase associated proteins
WO2000028045A3 (en) Human hydrolase proteins

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US US US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US US US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2379801

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 10031904

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2000948891

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000948891

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000948891

Country of ref document: EP